Lovenox Clears FDA For STEMI After Priority Review
This article was originally published in The Pink Sheet Daily
The low molecular weight heparin joins Plavix in the STEMI space.
You may also be interested in...
Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Sanofi's low molecular weight heparin has an early June user fee date for a STEMI claim.